Lucy Scientific Discovery (NASDAQ: LSDI) Acquisitions Create ‘Golden Opportunity’ for Growth, Success

并购引进/卖出
Lucy Scientific Discovery (NASDAQ: LSDI) Acquisitions Create ‘Golden Opportunity’ for Growth, Success
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lucy Scientific Discovery (NASDAQ: LSDI) announces the availability of a broadcast titled, “From Instagram to High Times: Unpacking the Power of Vast User Networks.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please visit: https://nnw.fm/aK4Qa
Enter Lucy Scientific Discovery (NASDAQ: LSDI), a company that has recognized the value in this counterintuitive approach. Lucy’s recent share purchase agreement to acquire the total intellectual property (IP) of High Times shows that the company truly understands the immense value of a large, loyal audience. In an all-stock transaction, the acquisition provides a stream of high-margin licensing and royalty income from the well-regarded High Times. More importantly, with its massive following, the High Times acquisition offers a golden opportunity for Lucy Scientific Discovery to introduce and distribute its products to a captive, engaged audience, while benefitting from significant early-stage revenue.
On closing, Lucy will acquire all the brand rights and fully intends to monetize the broad-based IP through both current and future royalty agreements. Lucy also plans to extend and enhance the existing domestic and international licensing arrangements currently held by High Times, including consumer products and merchandise. The company expects to preserve the core essence of the High Times brands and its followers while simultaneously expanding the follower base and pursuing new avenues of growth and development.
Lucy Scientific Discovery is a NASDAQ-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery and its wholly owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver and manufacture pharmaceutical-grade active pharmaceutical ingredients (“APIs”) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental-health outcomes and enhancing well-being for individuals worldwide.
For more information about the company, visit www.LucyScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN


更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。